OrphoMed, clinical-stage biopharmaceutical company, named Mark Sostek, MD, its next CMO.
Here's what you should know:
1. Dr. Sostek is a gastroenterologist. In his new position, he will lead all of OrphoMed's clinical trials, including its current phase I trial concerning ORP-101, TiGenix's irritable bowel syndrome with diarrhea treatment.
2. He has 17-plus years experience in the biopharmaceutical industry. He most recently worked for Pfizer in the company's inflammation and immunology research unit. Before that, he was with AstraZeneca Pharmaceuticals.
3. Dr. Sostek earned his medical degree from Medford, Mass.-based Tufts University. He completed an internship and residency at University of Los Angeles Medical Center and a fellowship at Burlington, Mass.-based Lahey Clinic.
He said, "I am excited to join OrphoMed and lead the clinical development of its dimer therapeutics, which have shown the potential to be best-in-class agents. Patients with gastrointestinal disorders need better therapeutic options for these painful and difficult-to-treat diseases. I am eager to advance the clinical development of ORP-101, as well as the other therapeutic candidates in the pipeline."